NASDAQ · ALNY
Healthcare · Biotechnology
$232.68
Up+$8.15 (+3.63%)
Updated Oct 10, 2026, 8:14 PM
SID Score
4.7/10
Composite research score
Smart Money
47/100
Neutral
Price performance · ALNY
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
ALNY closed at $232.68 after 21 trading sessions, down 6.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $224.74 | $232.935 | $222.705 | $232.68 | 959.45K |
| Oct 8, 2026 | $222.03 | $225.90 | $218.39 | $224.53 | 1.77M |
| Oct 7, 2026 | $224.39 | $230.42 | $222.46 | $224.41 | 1.06M |
| Oct 6, 2026 | $221.015 | $229.18 | $217.18 | $223.94 | 1.36M |
| Oct 5, 2026 | $218.36 | $222.08 | $215.46 | $219.89 | 1.28M |
| Oct 2, 2026 | $231.31 | $231.36 | $219.40 | $219.72 | 1.66M |
| Oct 1, 2026 | $248.21 | $251.71 | $230.06 | $231.18 | 2.02M |
| Sep 30, 2026 | $253.68 | $254.44 | $246.66 | $246.74 | 1.04M |
| Sep 29, 2026 | $254.86 | $257.27 | $251.02 | $254.07 | 787.08K |
| Sep 28, 2026 | $256.28 | $256.60 | $248.12 | $255.36 | 1.15M |
| Sep 25, 2026 | $248.39 | $256.66 | $247.51 | $255.96 | 1.08M |
| Sep 24, 2026 | $246.51 | $251.81 | $245.52 | $249.59 | 933.74K |
| Sep 23, 2026 | $249.99 | $253.81 | $245.34 | $246.51 | 1.48M |
| Sep 22, 2026 | $246.86 | $255.5106 | $244.13 | $251.65 | 1.13M |
| Sep 21, 2026 | $240.37 | $247.10 | $237.965 | $244.32 | 1.15M |
| Sep 18, 2026 | $246.41 | $246.49 | $238.51 | $239.56 | 2.76M |
| Sep 17, 2026 | $242.60 | $245.63 | $239.50 | $245.51 | 1.01M |
| Sep 16, 2026 | $239.50 | $242.24 | $236.00 | $239.36 | 853.9K |
| Sep 15, 2026 | $246.99 | $247.425 | $237.44 | $238.27 | 2.18M |
| Sep 14, 2026 | $250.165 | $252.79 | $244.18 | $249.99 | 997.23K |
| Sep 11, 2026 | $248.05 | $254.08 | $246.01 | $248.68 | 1.18M |
The latest Smart Investors Daily articles mentioning ALNY.
Company
Market Activity
Research & News
ALNY research
Company profile and research snapshot.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Sep 30, 2026 | JP Morgan | Overweight | — |
| Sep 21, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 8, 2026 | Jefferies | Hold | — |
| Sep 2, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 1, 2026
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.0% on an annualized basis producing an average annual return of 14.01%. Currently, Alnylam Pharmaceuticals has a market
Benzinga · Sep 30, 2026
JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $375 to $369.
Yahoo · Sep 29, 2026
CAMBRIDGE, Mass., September 29, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of AMVUTTRA® (vutrisiran) ‘Play by Play,’ a U.S. educational initiative featuring former professional athletes living with the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) and the care teams who support them. Through personal stories and expert perspectives, ‘Play by Play’ aims to help people recognize the symptoms of ATTR-CM earl
Yahoo · Sep 28, 2026
Wall Street expects an even bigger rebound for this beaten-down biotech stock.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALNY.
